Although many areas of contention exist in trade relations between the United States and China, ties are strengthening between the two countries, particularly in the areas of science and technology.…
The post China and Potential Opportunity for Pharmac…
China and Potential Opportunity for Pharmaceutical Investments Read Post »
This article was originally published by Ravi Gupta, Thomas J Bollyky, Matthew Cohen, Joseph S Ross, and Aaron S Kesselheim in BMJ 2018;360:k831 under a Creative Commons Attribution Non Commercial (CC BY-NC…
The post Affordability and availability of …
Officially known as Approved Drug Products With Therapeutic Equivalence Evaluations, the FDA Orange Book contains a list of drugs considered by the FDA as both effective and safe. It does…
The post 3 Uses for Historical Versions of the FDA Orange Book …
3 Uses for Historical Versions of the FDA Orange Book Read Post »
While the Patent Trial and Appeal Board invalidates Orange Book-listed patents less than 20 percent of the time, it accepts 66 percent of petitions from generic drugmakers and takes no…
The post What We Know From 4-Plus Years of Drug Patent Chall…
What We Know From 4-Plus Years of Drug Patent Challenges Heard by the PTAB Read Post »
Combination products offer companies new directions for drug patent innovation. Medicine has become more personalized over the past generation, and this has affected the drug patent system. One major trend…
The post Patents for Combination Produc…
Patents for Combination Products: Challenges and Opportunities Read Post »
This article was originally published by Andrew M Hill, Melissa J Barber, and Dzintars Gotham in BMJ Global Health Jan 2018, 3 (1) e000571 under a Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license. Abstract Introduction There are persi…
Estimated costs of production and potential prices for the WHO Essential Medicines List Read Post »
By Larry Ramer, DrugPatentWatch writer A growing number of pharmaceutical companies are looking to simultaneously benefit from the low costs of developing generic treatments and the increased market share and…
The post Biobetters, Supergenerics H…
Biobetters, Supergenerics Hold Many Advantages for Pharma Companies Read Post »
This is a guest post from Susan K Finston, President of Finston Consulting. A little over five years ago I penned
Biotech in Countries Starting with “I” – Part 12: Israel Read Post »
Health care costs in the US touched a staggering $3.2 trillion in 2015, which makes it one of the nation’s largest industries, equaling 17.8% of gross domestic product. This translates…
The post Factors driving healthcare costs in the US appeared…
Developing nations offer welcoming and growing markets as Abbott focuses exclusively on reformulating and marketing off-patent medications Driven by patient loyalty, prescriber preference, pharmacist trust, and traditional marketing, branded generics&#…
Branded Generics Promise Profits for Drugmakers, Peace of Mind for Patients Read Post »